Eczema drug dupilumab shows promise in skin of color patients

NCT ID NCT05590585

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of life in this specific group. Results showed that many patients achieved significant skin clearance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (Dupixent)
What this could lead to: If successful, this study could confirm that dupilumab works well for people with darker skin tones, leading to better treatment options for eczema in this group.
What could go wrong: This is a small, single-arm study without a placebo group, so results may not be definitive. Side effects like injection reactions or eye inflammation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC ECZEMA MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Show contact details

Locations

Advanced Medical Research PC

Atlanta, Georgia, 30328, United States
Atlanta Biomedical Clinical Research LLC

Atlanta, Georgia, 30331, United States
C2 Research Center, LLC

Montgomery, Alabama, 36117, United States
Callender Dermatology and Cosmetic Center

Glenn Dale, Maryland, 20769, United States
Center for Clinical Studies, LTD.LLP

Houston, Texas, 77004, United States
Center for Dermatology Clinical Research, inc.

Fremont, California, 94538, United States
Century Research LLC

Miami, Florida, 33173, United States
Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners

Rockville, Maryland, 20850, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Heights Dermatology & Aesthetic Center - Heights Location

Houston, Texas, 77008, United States
Markowitz Medical

New York, New York, 10128, United States
NYC Health + Hospital , Elmhurst Hospital Center

Elmhurst, New York, 11373, United States
National Allergy and Asthma Research, LLC.

North Charleston, South Carolina, 29420, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Philip Fried, MD PLLC

The Bronx, New York, 10463, United States
RFSA Dermatology

San Antonio, Texas, 78213, United States
Rao Dermatology

Atlantic Highlands, New Jersey, 07716, United States
Revival Research Institute , LLC

Troy, Michigan, 48084, United States
SF Research Institute

San Francisco, California, 94127, United States
SUNY Downstate Medical Center

Brooklyn, New York, 11203, United States
Skin and Cancer Associates, LLP

Miami, Florida, 33137, United States
Texas Dermatology and Laser Specialists

San Antonio, Texas, 78218, United States
The University Of Alabama At Birmingham

Birmingham, Alabama, 35233, United States
Total Skin & Beauty Dermatology Center

Birmingham, Alabama, 35203, United States
UCSD/ Rady Children's Hospital

San Diego, California, 92123, United States
UCSF

San Francisco, California, 94118, United States
University of Miami Miller School of Medicine

Miami, Florida, 33136, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne State University Physician Group Dermatology

Dearborn, Michigan, 48126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.